"alpha-Fetoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
| Descriptor ID |
D000509
|
| MeSH Number(s) |
D12.776.124.790.106.092 D12.776.320.525.500 D12.776.377.228.500 D12.776.377.715.085.092 D23.101.140.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "alpha-Fetoproteins".
Below are MeSH descriptors whose meaning is more specific than "alpha-Fetoproteins".
This graph shows the total number of publications written about "alpha-Fetoproteins" by people in this website by year, and whether "alpha-Fetoproteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Fetoproteins" by people in Profiles.
-
Elevation of Maternal Serum a-Fetoprotein: Implications for the Neonate. Neoreviews. 2024 Feb 01; 25(2):e117-e121.
-
Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
-
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 12 09; 27(12):e938-e948.
-
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305.
-
Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol. 2022 01; 20(1):204-215.e6.
-
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397.
-
Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193.
-
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020.
-
A biomimetic fluorescent nanosensor based on imprinted polymers modified with carbon dots for sensitive detection of alpha-fetoprotein in clinical samples. Analyst. 2019 Nov 04; 144(22):6760-6772.
-
Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms. J Pediatr Surg. 2020 Jan; 55(1):122-125.